相似文献
1
Active immunotherapy of cancer for minimal residual disease: new trends and new materials.
Prog Exp Tumor Res. 1980;25:242-74. doi: 10.1159/000403185.
2
Immunotherapy of human cancer.
Adv Intern Med. 1977;22:145-85.
3
Manipulation of host resistance in cancer therapy.
Springer Semin Immunopathol. 1982;5(2):113-25. doi: 10.1007/BF00199791.
4
Radiation therapy and immunotherapy: the value of immunotherapy in the control of local and regional cancer.
Cancer. 1976 Apr;37(4 Suppl):2108-19.
5
Immune adjuvant therapy in lung cancer.
Prog Exp Tumor Res. 1980;25:229-41. doi: 10.1159/000403184.
6
Immunotherapy of cancer: current status.
Prog Exp Tumor Res. 1980;25:61-88. doi: 10.1159/000403177.
7
Post-surgical systematic active immunotherapy: rational and experimental basis.
Recent Results Cancer Res. 1979;67:132-50. doi: 10.1007/978-3-642-81320-7_20.
8
Immunotherapy of lung cancer. I. Review of clinical trials in non-small cell histologic types.
Cancer Treat Rev. 1979 Sep;6(3):177-90. doi: 10.1016/s0305-7372(79)80069-9.
9
Fundamentals of active specific immunotherapy of cancer using BCG-tumor cell vaccines.
Prog Clin Biol Res. 1989;310:51-65.
10
Cancer active immunotherapy. Immunoprophylaxis and immunorestoration. An introduction.
Recent Results Cancer Res. 1976;55:1-402.
引用本文的文献
1
Adjuvant Bestatin immunotherapy in patients with transitional cell carcinoma of the bladder. Clinical results of a randomized trial.
Cancer Immunol Immunother. 1987;25(1):41-6. doi: 10.1007/BF00199299.
Zotero 插件